Abstract
Aim In this study we aim to identify the risk factors for treatment inertia in patients with type 2 diabetes mellitus (T2DM) who have been recently started on basal insulin (BI).
Methods Using UK CPRD GOLD, we identified adults with T2DM with suboptimal glycaemia (HbA1c within 12 months of BI ≥7% (≥53 mmol/mol)). We used multivariable Cox regression model to describe the association between patient characteristics and the time to treatment intensification.
Results A total of 12,556 patients were analysed. Compared to individuals aged <65 years, those aged ≥65 years had lower risk of treatment intensification (HR: 0.69; 95% CI: 0.64-0.73). Other risk factors included being female (0.93, 0.89-0.99), longer T2DM duration (0.99, 0.98-0.99), living in the most deprived areas (0.90, 0.83-0.98), being a current smoker (0.91, 0.84-0.98), having one (0.91, 0.85- 0.97) or more than one comorbidity (0.88, 0.82-0.94), and patients who were on metformin (0.71, 0.63-0.80), or 2nd generation sulphonylureas (0.85; 0.79-0.92) or DPP4 inhibitors (0.87, 0.82-0.93) compared to those who were not.
Conclusion Therapeutic inertia still remains a major barrier, with multiple factors associated with delay in intensification. Interventions to overcome therapeutic inertia need to be implemented at both patient and health care professional level.
Competing Interest Statement
M.J.D. has served as consultant, advisory board member and speaker for Novo Nordisk, Sanofi-Aventis, Lilly, Merck Sharp & Dohme, Boehringer Ingelheim, AstraZeneca and Janssen; an advisory board member for Servier and Gilead Sciences Ltd; as a speaker for NAPP, Mitsubishi Tanabe Pharma Corporation, and Takeda Pharmaceuticals International Inc; and received grants in support of research trials from Novo Nordisk, Sanofi-Aventis, Lilly, Boehringer Ingelheim, AstraZeneca, and Janssen. K.K. has served as a consultant and participated in speaker bureaus for, or received research support from, Amgen, AstraZeneca, Berlin-Chemie AG/Menarini Group, BMS, Boehringer Ingelheim, Janssen, Lilly, MSD, Napp, Novartis, Novo Nordisk, Roche, Sanofi and Servier. Sam.S. reports personal fees from NAPP, Amgen, Astra Zeneca, Lilly, Merck Sharp & Dohme, Novartis, Novo Nordisk, Roche, Boehringer Ingelheim, Sanofi-Aventis, grants from AstraZeneca, Sanofi-Aventis, Servier and Janssen, outside the submitted work. T.D. is an employee of Sanofi US, Inc. D.R.W. has received grant in support of investigator-initiated studies and honoraria from Sanofi-Aventis and Novo Nordisk. The remaining authors have nothing to disclose.
Funding Statement
This research was supported by Sanofi (New Jersey, USA).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study was conducted using CPRD GOLD and linked data subject to protocol approval (ISAC Protocol 19_047). The data controller for CPRD (Department of Health and Social Care) does not allow sharing of raw data. CPRD has ethics approval from the Health Research Authority to support research using anonymised patient data. Linked pseudonymised data was provided for this study by CPRD. Data is linked by NHS Digital, the statutory trusted third party for linking data, using identifiable data held only by NHS Digital. Select general practices consent to this process at a practice level with individual patients having the right to opt-out.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
